Cover Image

Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer: a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system

In the ‘Arimidex’, Tamoxifen Alone or in Combination (ATAC) trial, the aromatase inhibitor (AI) anastrozole had a significantly better efficacy and safety profile than tamoxifen as initial adjuvant therapy for hormone receptor-positive (HR+) early breast cancer (EBC) in postmenopausal patients. To c...

Full description

Saved in:
Bibliographic Details
Main Authors: Lux, Michael Patrick (Author) , Wöckel, Achim (Author) , Benedict, Agnes (Author) , Buchholz, Stefan (Author) , Kreif, Noémi (Author) , Harbeck, Nadia (Author) , Kreienberg, Rolf (Author) , Kaufmann, Manfred (Author) , Beckmann, Matthias Wilhelm (Author) , Jonat, Walter (Author) , Hadji, Peyman (Author) , Distler, Wolfgang (Author) , Raab, Guenther (Author) , Tesch, Hans (Author) , Weyers, Georg (Author) , Possinger, Kurt (Author) , Schneeweiss, Andreas (Author)
Format: Article (Journal)
Language:English
Published: March 19, 2010
In: Oncology research and treatment
Year: 2010, Volume: 33, Issue: 4, Pages: 155-166
ISSN:2296-5262
DOI:10.1159/000286233
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1159/000286233
Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/286233
Get full text
Author Notes:Michael P. Lux, Achim Wöckel, Agnes Benedict, Stefan Buchholz, Noé, Mi Kreif, Nadia Harbeck, Rolf Kreienberg, Manfred Kaufmann, Matthias W. Beckmann, Walter Jonat, Peyman Hadji, Wolfgang Distler, Guenther Raab, Hans Tesch, Georg Weyers, Kurt Possinger, Andreas Schneeweiss
Description
Summary:In the ‘Arimidex’, Tamoxifen Alone or in Combination (ATAC) trial, the aromatase inhibitor (AI) anastrozole had a significantly better efficacy and safety profile than tamoxifen as initial adjuvant therapy for hormone receptor-positive (HR+) early breast cancer (EBC) in postmenopausal patients. To compare the combined long-term clinical and economic benefits, we carried out a cost-effectiveness analysis (CEA) of anastrozole versus tamoxifen based on the data of the 100month analysis of the ATAC trial from the perspective of the German public health insurance. Patients and Methods: A Markov model with a 25-year time horizon was developed using the 100-month analysis of the ATAC trial as well as data obtained from published literature and expert opinion. Results: Adjuvant treatment of EBC with anastrozole achieved an additional 0.32 quality-adjusted life-years (QALYs) gained per patient compared with tamoxifen, at an additional cost of D 6819 per patient. Thus, the incremental cost effectiveness of anastrozole versus tamoxifen at 25 years was D 21,069 ($30,717) per QALY gained. Conclusions: This is the first CEA of an AI that is based on extended follow-up data, taking into account the carryover effect of anastrozole, which maintains the efficacy benefits beyond therapy completion after 5 years. Adjuvant treatment with anastrozole for postmenopausal women with HR+ EBC is a cost-effective alternative to tamoxifen.
Item Description:Gesehen am 20.04.2023
Physical Description:Online Resource
ISSN:2296-5262
DOI:10.1159/000286233

Similar Items